My primary research interests include the immunotherapy of cancer (including stem cell transplantation), the identification of B-cell-tumour antigens; and the detection and treatment of minimal residual disease in leukaemia and lymphoma.
Expression of FOXP3, CD68 and CD20 at Diagnosis in the Microenvironment of Classical Hodgkin Lymphoma is Predictive of outcome. J Clin Oncol (2013) 31(2):256-62. PMID: 23045593
E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci USAÂ (2009) 106(15):6250-5. PMID:Â 19332800
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest (2008) 118(7):2427-37. PMID: 18551193
SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL. Blood (2008) 112(2):394-7. PMID: 18434611
The research interest of my group focuses on immunological approaches to the treatment of haematological cancers. In particular, we are interested in understanding:
Need for risk adjustment in comparative effectiveness and cost-effectiveness studies in r/r follicular lymphoma. Gribben JG, Palomba ML, Patel AR et al. Blood Adv (2023) (2)
https://www.ncbi.nlm.nih.gov/pubmed/36661331
Bridging Chemotherapy: Follicular Lymphoma, Mantle Cell Lymphoma, and CLL Gagelmann N, Gribben J, Kröger N (2022) (18)
Educational Needs for Physicians Kröger N, Gribben J, Sánchez-Ortega I (2022) (18)
Evaluating an interactive acceptance and commitment therapy (ACT) workshop delivered to trained therapists working with cancer patients in the United Kingdom: a mixed methods approach Moschopoulou E, Brewin D, Ridge D et al. BMC Cancer (2022) 22(7)
Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications Baptista MJ, Tapia G, Muñoz-Marmol AM et al. Histopathology (2022) 81(7) 826-840
Genomic profiling for clinical decision making in lymphoid neoplasms de Leval L, Alizadeh AA, Bergsagel PL et al. Blood (2022) 140(7) 2193-2227
A 3-Year Follow-up Comparison of Clinical Outcomes from Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL) Ghione P, Palomba ML, Ray MD et al. Blood (2022) 140(10) 4676-4677
Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML Rio-Machin A, Bewicke-Copley F, Zheng J et al. Blood (2022) 140(10) 1030-1032
Longitudinal Single Cell Analyses Reveal the Co-Evolutionary Dynamics of the Tumor and Microenvironment Accompanying Follicular Lymphoma Transformation Perrett M, Pickard L, Kumar E et al. Blood (2022) 140(10) 748-749
MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study Munir T, Cherrill L-R, Webster N et al. Blood (2022) 140(10) 222-223
For additional publications, please click hereGroup Leaders in the Centre
Dr Andrejs Braun, Dr Jeff Davies, Dr Gabriella Ficz, Professor Kamil R. Kranc, Dr Sergey Krysov, Dr Rifca Le Dieu, Dr Kevin Rouault-Pierre, Dr John Riches, Dr Bela Wrench
Clinical Research Fellows
Dr Jennifer Edelmann, Dr Robin Sanderson, Dr Joseph Taylor, Dr Edward Truelove
I hold the Gordon Hamilton Fairley Chair of Medical Oncology at St. Bartholomew's Hospital, Barts Cancer Institute, Queen Mary, University of London. My doctoral studies were performed at University College London as the recipient of a Wellcome Trust Fellowship Award. I continued post-doctoral training with Professor Lee Nadler at the Dana-Farber Cancer Institute, Harvard Medical School.
In 1992, I was appointed to the Faculty at Harvard Medical School, where I remained as Associate Professor of Medicine and an Attending Physician at the Dana-Farber Cancer Institute and Brigham and Women's Hospital, until returning to London in 2005. I am a founding member of the CLL Research Consortium, Associate Editor of Blood and was elected a Fellow of the Academy of Medical Science.